Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia

This retrospective study at the University of Texas MD Anderson Cancer Center evaluated frontline venetoclax combination therapy in 11 pediatric/adolescent patients with acute myeloid leukemia (AML). Despite the small sample size and retrospective nature, the treatment demonstrated safety and potent...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2024-11, Vol.71 (11), p.e31286-n/a
Main Authors: Gibson, Amber, Dickson, Samantha, McCall, David, Garcia, Miriam, Connors, Jeremy, He, Jiasen, Roth, Michael, Nunez, Cesar, Cuglievan, Branko
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Adolescent
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bridged Bicyclo Compounds, Heterocyclic - administration & dosage
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Infant
Leukemia, Myeloid, Acute - drug therapy
Male
Patients
pediatric
Pediatrics
Prognosis
Remission
Retrospective Studies
Sulfonamides - administration & dosage
Sulfonamides - therapeutic use
Survival Rate
Toxicity
venetoclax
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This retrospective study at the University of Texas MD Anderson Cancer Center evaluated frontline venetoclax combination therapy in 11 pediatric/adolescent patients with acute myeloid leukemia (AML). Despite the small sample size and retrospective nature, the treatment demonstrated safety and potential efficacy, with most patients achieving early complete remission. Adverse events were consistent with other AML therapies, and no discontinuations due to toxicity occurred. While acknowledging study limitations, including selection bias and diverse concurrent therapies, this research underscores the promising role of venetoclax in pediatric AML. Further investigation is crucial to validate its long‐term efficacy in this population.
ISSN:1545-5009
1545-5017
1545-5017
DOI:10.1002/pbc.31286